These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36005269)

  • 21. Evaluation of
    Suich J; Mawer D; van der Woude M; Wearmouth D; Burns P; Smeets T; Barlow G
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35476672
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections.
    Zhanel GG; Zhanel MA; Karlowsky JA
    Can J Infect Dis Med Microbiol; 2020; 2020():8513405. PubMed ID: 32300381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?
    Gardiner BJ; Mahony AA; Ellis AG; Lawrentschuk N; Bolton DM; Zeglinski PT; Frauman AG; Grayson ML
    Clin Infect Dis; 2014 Feb; 58(4):e101-5. PubMed ID: 24170195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
    Neuner EA; Sekeres J; Hall GS; van Duin D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT; May DB
    Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fosfomycin: Resurgence of an old companion.
    Sastry S; Doi Y
    J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of Nitrofurantoin and Fosfomycin Against Outpatient Urinary Isolates of Multidrug-Resistant Enterococci over a Period of 10 Years from India.
    Das A; Banerjee T; Anupurba S
    Microb Drug Resist; 2020 Dec; 26(12):1509-1515. PubMed ID: 31794690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible
    Dunne MW; Puttagunta S; Aronin SI; Brossette S; Murray J; Gupta V
    Microbiol Spectr; 2022 Feb; 10(1):e0235921. PubMed ID: 35138150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Community-Acquired Uropathogenic
    Carmona-Cartaya Y; Hidalgo-Benito M; Borges-Mateus LM; Pereda-Novales N; González-Molina MK; Quiñones-Pérez D
    MEDICC Rev; 2022 May; 24(2):20-25. PubMed ID: 35648059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.
    Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG
    Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
    Sojo-Dorado J; López-Hernández I; Rosso-Fernandez C; Morales IM; Palacios-Baena ZR; Hernández-Torres A; Merino de Lucas E; Escolà-Vergé L; Bereciartua E; García-Vázquez E; Pintado V; Boix-Palop L; Natera-Kindelán C; Sorlí L; Borrell N; Giner-Oncina L; Amador-Prous C; Shaw E; Jover-Saenz A; Molina J; Martínez-Alvarez RM; Dueñas CJ; Calvo-Montes J; Silva JT; Cárdenes MA; Lecuona M; Pomar V; Valiente de Santis L; Yagüe-Guirao G; Lobo-Acosta MA; Merino-Bohórquez V; Pascual A; Rodríguez-Baño J;
    JAMA Netw Open; 2022 Jan; 5(1):e2137277. PubMed ID: 35024838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.